SCHEMBL1673932

SCHEMBL1673932

CCC(c1ccccc1)N(Cc1ccc(C(=O)NN2CCOCC2)cc1)S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.53
PSEN1 P49768 1/20 0.52
PSEN2 P49810 1/20 0.52
APH1B Q8WW43 1/20 0.52
NCSTN Q92542 1/20 0.52
APH1A Q96BI3 1/20 0.52
PSENEN Q9NZ42 1/20 0.52
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 1/20 0.45
CXCR3 P49682 6/20 0.44
LMNA P02545 1/20 0.44
RAB9A P51151 1/20 0.44
GAA P10253 1/20 0.43
TAS2R14 Q9NYV8 3/20 0.43
MEN1 O00255 2/20 0.43
TP53 P04637 1/20 0.43
NPC1 O15118 1/20 0.43
CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15388164 1.00 SMN1; SMN2 (0.53) SMN1; SMN2PSEN1PSEN2APH1BNCSTN
SCHEMBL1674416 0.89 PSEN1 (0.52) SMN1; SMN2PSEN1PSEN2APH1BNCSTN
SCHEMBL15387993 0.89 PSEN1 (0.52) SMN1; SMN2PSEN1PSEN2APH1BNCSTN
SCHEMBL10205301 0.86 PSEN1 (0.50) SMN1; SMN2PSEN1PSEN2APH1BNCSTN
SCHEMBL15392617 0.86 PSEN1 (0.50) SMN1; SMN2PSEN1PSEN2APH1BNCSTN
SCHEMBL15388269 0.85 CXCR3 (0.61) SMN1; SMN2PSEN1PSEN2APH1BNCSTN
SCHEMBL1673402 0.85 CXCR3 (0.61) SMN1; SMN2PSEN1PSEN2APH1BNCSTN
SCHEMBL15388034 0.84 PSEN1 (0.58) SMN1; SMN2PSEN1PSEN2APH1BNCSTN
SCHEMBL10206392 0.83 PSEN1 (0.57) SMN1; SMN2PSEN1PSEN2APH1BNCSTN
SCHEMBL15388487 0.83 PSEN1 (0.57) SMN1; SMN2PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310384-A1 Sulfonamide-Containing Compounds THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2013-11-21 US disclosed
WO-2012047926-A2 SULFONAMIDE-CONTAINING COMPOUNDS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310384-A1 Sulfonamide-Containing Compounds BACE1, BACE2, GSAP SMN1; SMN2 878/4885PSEN1 4/4885PSEN2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.